stockrow
Friday 6 November 2026
Export CELC’s income statement to Excel — free account
Celcuity, Inc.
CELC Healthcare Biotechnology
- EPS
- −38.5%
- Free cash flow
- −53.3%
- Total debt
- +658.7%
Quarter to June 2026, against a year earlier
66.82
2.78
+4.34%
Follow CELC
Alert me
Celcuity, Inc. (CELC) Book value per share
Celcuity, Inc.'s book value per share at the end of fiscal 2025 was 2.2×, down 26.6% from 2.9× in fiscal 2024. At the end of the quarter to 30 June 2026 it was −0.2×. Over the past ten years it has ranged from 0.9× (fiscal 2015) to 8.7× (fiscal 2022); the current reading is higher than 45% of that period. Celcuity, Inc. ranks 549th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 2.2× | (26.62%) |
| FY2024 | 2.9× | (50.35%) |
| FY2023 | 5.9× | (31.96%) |
| FY2022 | 8.7× | 68.98% |
| FY2021 | 5.1× | 350.45% |
| FY2020 | 1.1× | (39.60%) |
| FY2019 | 1.9× | (24.63%) |
| FY2018 | 2.5× | (40.49%) |
| FY2017 | 4.2× | 373.33% |
| FY2016 | 0.9× | 3.54% |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | −0.2× | — |
| Mar 2026 | 1.0× | (54.30%) |
| Dec 2025 | 2.2× | (12.50%) |
| Sep 2025 | 2.5× | 141.83% |
| 37 more quarters | Free account |
Against its own ten years
Low 0.9×
High 8.7×
Ten-year median
2.5×
Current reading's percentile
45
Book value per share against peers
| Company | Book value per share |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 13.5× |
| IDYA IDEAYA Biosciences, Inc. compare | 10.6× |
| VKTX Viking Therapeutics, Inc. compare | 5.0× |
| DNLI Denali Therapeutics Inc. compare | 4.9× |
| DYN Dyne Therapeutics, Inc. compare | 4.2× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 2.2× |
| VRDN Viridian Therapeutics, Inc. compare | 0.0× |
| TLX Telix Pharmaceuticals Limited compare | 0.0× |
| CELC Celcuity, Inc. | −0.2× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))